Global Premature Ejaculation Treatment Market 2017-2021

  • ID: 4427382
  • Report
  • Region: Global
  • 84 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Bayer
  • Dong-A Pharmaceutical
  • Eli Lilly
  • Emcure
  • Futura Medical
  • GlaxoSmithKline
  • MORE
About Premature Ejaculation Treatment

Premature ejaculation is one of the most common sexual dysfunctions occurring in men. Ejaculation happens sooner than desired, either shortly or before penetration, resulting in distress to either one or both partners involved in sexual intercourse. There is no exact cause that can be associated with the condition though mostly, premature ejaculation can be attributed to personal distress and anxiety. It can affect an individual's relationship with his partner. Premature ejaculation is the most common sexual disorder found in men aged between 18 to 59. Some of the effective treatment options available include psychological counseling, medications, sexual techniques that delay ejaculation, or a combination of these treatments.

The analysts forecast the global premature ejaculation treatment market to grow at a CAGR of 8.71% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global premature ejaculation treatment market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Premature Ejaculation Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
  • Absorption Pharmaceuticals
  • Bayer
  • Eli Lilly
  • Regent Pacific Group
Other prominent vendors
  • Dong-A Pharmaceutical
  • Emcure
  • Futura Medical
  • GlaxoSmithKline
  • NeuroHealing Pharmaceuticals
  • Pfizer
Market drivers
  • High use of off-label drugs
  • For a full, detailed list, view the full report
Market challenges
  • Alternative treatments
  • For a full, detailed list, view the full report
Market Trends
  • Growing online retail sales of drugs
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer
  • Dong-A Pharmaceutical
  • Eli Lilly
  • Emcure
  • Futura Medical
  • GlaxoSmithKline
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
  • Market outline
PART 05: PREMATURE EJACULATION: DISEASE OVERVIEW

PART 06: MARKET LANDSCAPE
  • Market overview
  • Five forces analysis
PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION
  • Oral route of administration
  • Topical route of administration
PART 09: MARKET SEGMENTATION BY DRUG CLASS
  • SSRIs
  • PDE5 inhibitors
  • Amide anesthetics
  • Others
PART 10: REGIONAL LANDSCAPE
  • Regional comparison
  • Premature ejaculation treatment market in Americas
  • Premature ejaculation treatment market in EMEA
  • Premature ejaculation treatment market in APAC
  • Key leading countries
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • Growing online retail sales of drugs
  • Increase in awareness of premature ejaculation
  • New treatment methods
PART 14: VENDOR LANDSCAPE
  • Competitive scenario
PART 15: KEY VENDOR ANALYSIS
  • Absorption Pharmaceuticals
  • Bayer
  • Eli Lilly
  • Regent Pacific Group
  • Other prominent vendors
PART 16: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Global premature ejaculation treatment market: Overview
Exhibit 02: Facts about premature ejaculation
Exhibit 03: Severity levels of premature ejaculation
Exhibit 04: Clinical diagnosis of premature ejaculation
Exhibit 05: Premature ejaculation classification
Exhibit 06: Global premature ejaculation treatment market 2016-2021 ($ millions)
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline molecules by vendors
Exhibit 09: Key clinical trials
Exhibit 10: Global premature ejaculation treatment market by route of administration 2016
Exhibit 11: Global premature ejaculation treatment market by SSRIs 2016-2021 ($ millions)
Exhibit 12: Global premature ejaculation treatment market by PDE5 inhibitors 2016-2021 ($ millions)
Exhibit 13: Global premature ejaculation treatment market by amide anesthetics 2016-2021 ($ millions)
Exhibit 14: Global premature ejaculation treatment market by others 2016-2021 ($ millions)
Exhibit 15: Global premature ejaculation treatment market by region 2016-2021 (% share)
Exhibit 16: Regional comparison
Exhibit 17: Premature ejaculation treatment market in Americas 2016-2021 ($ millions)
Exhibit 18: Premature ejaculation treatment market in Americas – Year over year growth
Exhibit 19: Premature ejaculation treatment market in EMEA 2016-2021 ($ millions)
Exhibit 20: Premature ejaculation treatment market in EMEA – Year over year growth
Exhibit 21: Premature ejaculation treatment market in APAC 2016-2021 ($ millions)
Exhibit 22: Premature ejaculation treatment market in APAC – Year over year growth
Exhibit 23: Key leading countries
Exhibit 24: Pharmacologic efficacy of some SSRIs
Exhibit 25: Premature ejaculation treatment drugs and their subsequent side effects
Exhibit 26: Factors challenging the treatment of premature ejaculation
Exhibit 27: Absorption Pharmaceuticals: Key highlights
Exhibit 28: Absorption Pharmaceuticals: Strength assessment
Exhibit 29: Absorption Pharmaceuticals: Strategy assessment
Exhibit 30: Absorption Pharmaceuticals: Opportunity assessment
Exhibit 31: Bayer: Key highlights
Exhibit 32: Bayer: Strength assessment
Exhibit 33: Bayer: Strategy assessment
Exhibit 34: Bayer: Opportunity assessment
Exhibit 35: Eli Lilly: Key highlights
Exhibit 36: Eli Lilly: Strength assessment
Exhibit 37: Eli Lilly: Strategy assessment
Exhibit 38: Eli Lilly: Opportunity assessment
Exhibit 39: Regent Pacific Group: Key highlights
Exhibit 40: Regent Pacific Group: Strength assessment
Exhibit 41: Regent Pacific Group: Strategy assessment
Exhibit 42: Regent Pacific Group: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Bayer
  • Dong-A Pharmaceutical
  • Eli Lilly
  • Emcure
  • Futura Medical
  • GlaxoSmithKline
  • MORE
New Report Released: – Global Premature Ejaculation Treatment Market 2017-2021

The author of the report recognizes the following companies as the key players in the global premature ejaculation treatment market: Absorption Pharmaceuticals, Bayer, Eli Lilly, and Regent Pacific Group

Other Prominent Vendors in the market are: Dong-A Pharmaceutical, Emcure, Futura Medical, GlaxoSmithKline, NeuroHealing Pharmaceuticals, and Pfizer

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Growing online retail sales of drugs. The advent of the internet has reduced the time involved in the physical buying and selling of products and services for buyers and sellers. In terms of growth of different retail channels through which sexual disorder-related drugs are offered, online retailing will be the fastest channel of distribution during the forecast period. The success of online retailing can be attributed to factors such as the availability of a broad range of products, quick delivery services, and highly competitive prices.”

According to the report, one of the major drivers for this market is High use of off-label drugs. The global premature ejaculation treatment market has witnessed the increased use of off-label drugs belonging to different drug classes such as SSRIs (fluvoxamine, paroxetine, sertraline, and fluoxetine) and PDE5 inhibitors (Cialis, VIAGRA, and Levitra). Pharmacological modification of the ejaculatory response in patients with the condition represents a novel approach for the treatment of premature ejaculation and will lead to the gradual replacement of psychosexual counseling, which was previously regarded as the cornerstone of premature ejaculation treatment.

Further, the report states that one of the major factors hindering the growth of this market is Alternative treatments. While the market has several drugs in the pipeline, the growing number of premature ejaculation cases globally has led to an increase in the number of alternative treatment methods for the disease. Some of the alternate treatment methods include counseling, homeopathy, psychotherapy, yoga, and herbal therapy. There are also other natural treatment options for premature ejaculation such as ginseng tea or supplement, raw almond milk, and Ayurvedic dietary changes that can help in delaying ejaculation.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Absorption Pharmaceuticals
  • Bayer
  • Eli Lilly
  • Regent Pacific Group
  • Dong-A Pharmaceutical
  • Emcure
  • Futura Medical
  • GlaxoSmithKline
  • NeuroHealing Pharmaceuticals
  • Pfizer
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll